Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 5,086 recruiting studies in this area right now.
By phase
- Not applicable2,108
- Phase 21,118
- Phase 1823
- Phase 1/Phase 2484
- Phase 3349
- Phase 4126
- Phase 2/Phase 378
Top conditions
- Multiple Myeloma333
- Acute Myeloid Leukemia292
- Lymphoma182
- Sickle Cell Disease142
- Myelodysplastic Syndromes129
- Acute Lymphoblastic Leukemia123
- Chronic Lymphocytic Leukemia100
- Leukemia100
- Follicular Lymphoma74
- Hematologic Malignancy68
- Myelodysplastic Syndrome68
- Hodgkin Lymphoma67
- Mantle Cell Lymphoma62
- Anemia60
- Diffuse Large B Cell Lymphoma57
- Lymphedema49
- Non-Hodgkin Lymphoma49
- Small Lymphocytic Lymphoma49
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China148
- M.D. Anderson Cancer Center147
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University68
- Memorial Sloan Kettering Cancer Center65
- Mayo Clinic61
- City of Hope Medical Center60
- Assistance Publique - Hôpitaux de Paris46
- St. Jude Children's Research Hospital43
- Peking University People's Hospital41
Where studies are running
- California406
- Texas186
- Maryland149
- Alabama146
- Arizona123
- Florida111
- Massachusetts101
- New York98
- Ohio71
- Minnesota68
Recruiting studies5,086 total
- NCT07082725RecruitingPhase 3
Study of oral nizubaglustat for Niemann-Pick type C
This study tests an oral medication called nizubaglustat for people with Niemann-Pick type C disease who cannot take or are not satisfied with the current treatment miglustat. It aims to see if the drug can help with symptoms like coordination and movement problems.
Oakland, CaliforniaAges 4 years+ - NCT05110742RecruitingPhase 1/Phase 2
CD5-targeting NK cell therapy for blood cancers
This trial tests a new kind of immune cell therapy (NK cells) that are made to attack cancer cells carrying the CD5 marker. You will have a short course of chemotherapy before the infusion to help the cells work. It is for people with certain blood cancers that have not responded to standard treatments.
Houston, TexasAges 18 years+ - NCT07652281RecruitingPhase 1
Study of SHR-5421 for multiple myeloma
This trial tests a new drug, SHR-5421, for people with multiple myeloma that has come back or stopped responding to treatment. It aims to see if the drug is safe and how well it works.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07424833RecruitingPhase 1
Study of APG-3288 for Relapsed/Refractory Blood Cancers
This trial is testing a new drug called APG-3288 for people with certain relapsed or treatment-resistant blood cancers (like CLL/SLL, DLBCL, MCL, WM, MZL, or FL). You may qualify if you've tried at least 2 prior treatments and are looking for a new option.
Los Angeles, CaliforniaAges 18 years+ - NCT06785818Recruiting
Long-term follow-up of Kymriah patients in South Korea
This study follows patients in South Korea who have already received Kymriah (tisagenlecleucel) in a real-world setting. It aims to monitor their long-term health and any side effects over time.
Bundang Gu, Gyeonggi-doAges birth–100 years - NCT07630545RecruitingPhase 1
Testing a new drug for Parkinson's disease
This study tests an experimental drug, MTX325, in people with Parkinson's disease. The goal is to see if it is safe and how the body processes it, which may lead to new treatment options.
AdelaideAges 18–75 - NCT04169737RecruitingPhase 2
Acalabrutinib and venetoclax for high-risk CLL or SLL
This trial tests whether acalabrutinib and venetoclax (with or without early obinutuzumab) can control chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It is mainly for people whose disease is high-risk, has come back, or did not respond to earlier treatment.
Houston, TexasAges 18 years+ - NCT05365659RecruitingPhase 1
Testing IKS03 for advanced B-cell lymphoma
This trial tests a new study drug, IKS03, for people with advanced B-cell non-Hodgkin lymphoma that has not responded to at least two prior treatments. The goal is to see if the drug is safe and how well it works.
Baltimore, MarylandAges 18 years+ - NCT06516679RecruitingPhase 2
Customized treatment for infants with newly diagnosed leukemia
This trial tests a treatment plan that adjusts therapy based on each baby's risk level. It aims to improve outcomes for infants newly diagnosed with certain types of leukemia.
DaeguAges Up to 2 years - NCT07730515RecruitingPhase 1/Phase 2
Study of XNW5004 plus chemo for untreated T-cell lymphoma
This trial tests a new drug called XNW5004 combined with standard chemotherapy for people who have just been diagnosed with peripheral T-cell lymphoma and haven't had treatment yet. The goal is to see if adding XNW5004 helps more than chemotherapy alone.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06257394RecruitingPhase 2
Treating high-risk childhood leukemia in Korea
This trial tests a new treatment plan for children with very high-risk acute lymphoblastic leukemia. It aims to improve outcomes for patients whose leukemia has specific genetic markers or has not responded well to initial treatment.
DaeguAges 1–19 - NCT05827549RecruitingPhase 2
Blinatumomab for relapsed ALL, matched by risk group
This Phase 2 study tests how well blinatumomab works for children and adults whose acute lymphoblastic leukemia (ALL) has come back. It also looks at whether results differ based on the patient’s relapse “risk group.”
DaeguAges 1–22 - NCT05828069RecruitingPhase 2
Tovorafenib for young people with worsening Langerhans cell histiocytosis
This Phase 2 trial tests tovorafenib (DAY101) to treat children and young people whose Langerhans cell histiocytosis (LCH) is getting worse, came back, or did not respond to prior treatment. It may help by targeting certain gene changes found in the LCH.
Birmingham, AlabamaAges 6 months–22 years - NCT02447874RecruitingPhase 1/Phase 2
Arginine treatment for children’s sickle cell pain
This early-phase study tests whether arginine can help control pain in children with sickle cell disease. You may be considered if your child is having a sickle cell pain episode that needs stronger pain medicine given through an IV.
Atlanta, GeorgiaAges 7–21 - NCT05334368RecruitingPhase 3
Depemokimab for hypereosinophilic syndrome with frequent flares
This trial studies depemokimab, a medicine meant to reduce flares in people with hypereosinophilic syndrome (HES). It also checks how safe the treatment is and how well it works over time.
San Diego, CaliforniaAges 18 years+ - NCT07478991RecruitingPhase 3
Azacitidine and venetoclax with or without quizartinib for older or unfit AML patients
This trial tests if adding quizartinib to the standard combination of azacitidine and venetoclax improves outcomes for older adults or those with health conditions who cannot have intensive chemotherapy for acute myeloid leukemia (AML). It may help patients with certain genetic changes in the FLT3 or NPM1 genes.
Santiago de Compostela, A CoruñaAges 18 years+ - NCT07397832RecruitingPhase 2
CRP drug combo for older adults with untreated double-positive DLBCL
This trial tests a new combination of drugs (CRP regimen) for older patients who have not yet been treated for a specific type of DLBCL called double-expressor lymphoma. It aims to see if this combination is effective and safe for people who may not be able to get standard chemotherapy.
Tianjin, Tianjin MunicipalityAges 60 years+ - NCT05645107RecruitingPhase 3
XEMBIFY plus usual care to prevent infections
This Phase 3 study tests whether XEMBIFY (an immune protein therapy) plus standard medical treatment can better prevent serious or repeated infections. It is for people with certain cancers of blood/immune systems who are already having trouble with infections.
Huntington Park, CaliforniaAges 18 years+ - NCT06184009RecruitingPhase 2
Treatment for high-risk childhood leukemia
This trial tests a new treatment approach for children and teens with high-risk acute lymphoblastic leukemia (ALL). It aims to improve outcomes for those with certain genetic changes or cancer that has spread.
Seoul, SeoulAges 1–19 - NCT06616636RecruitingPhase 1
Rezatapopt and azacitidine for AML or MDS with a specific TP53 mutation
This trial tests a new drug, rezatapopt, combined with azacitidine for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back or not responded to treatment. It is only for people whose cancer cells have a specific change in a gene called TP53 (the Y220C mutation). The goal is to see if this combination can help control the disease.
Tampa, FloridaAges 18 years+ - NCT04840602RecruitingPhase 2
Venetoclax plus rituximab versus standard Waldenstrom treatment
This trial tests whether adding venetoclax to rituximab works better than standard treatment options for Waldenstrom’s macroglobulinemia (WM). It’s for adults whose WM needs treatment and who meet specific blood, organ, infection, and medication safety requirements.
Tucson, ArizonaAges 18 years+ - NCT06773195RecruitingPhase 1/Phase 2
Study of Ruxolitinib and Ulixertinib for Myelofibrosis
This trial tests a new combination of two drugs, ruxolitinib and ulixertinib, for people with myelofibrosis whose disease is not fully controlled by ruxolitinib alone. The goal is to see if adding ulixertinib can improve spleen enlargement, symptoms, or bone marrow changes.
Boston, MassachusettsAges 18 years+ - NCT07024563RecruitingPhase 3
Testing ravulizumab for kids with IgA nephropathy
This study tests a drug called ravulizumab for children aged 2 to under 18 with IgA nephropathy, a kidney condition. It aims to see if the drug can help protect the kidneys and reduce protein in the urine.
Palo Alto, CaliforniaAges 2–18 - NCT07191119Recruiting
Nerve stimulation for insomnia in childhood leukemia survivors
This study tests a small, wearable device that gently stimulates a nerve in your ear (called the vagus nerve) to help with insomnia. It's designed for adult survivors of childhood leukemia who still have trouble sleeping.
Memphis, TennesseeAges 20–50
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 5,086 recruiting hematology studies from the U.S. registry right now, out of 7,699 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.